NEW DELHI, Mar 24: Drug firm Suven Life Sciences has been granted patents each by Canada, Japan and Korea for molecules, aimed to be developed as drugs, for the treatment of neuro-degenerative diseases.
The patents are valid through 2030, Suven Life Sciences said in a filing to the BSE.
Commenting on the development, Suven Life CEO Venkat Jasti said: “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”
The granted patents include the class of selective 5-HT compounds discovered by the company and are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer’s disease, Huntington’s disease, Parkinson and Schizophrenia, among others, Suven said.
“With these new patents, Suven has a total of eighteen granted patents from Canada, sixteen granted patents from Japan and sixteen product patents from Korea,” it added.
These patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts, Suven said.
“Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II,” it added.
Trending Now
E-Paper
Follow our WhatsApp channel